key: cord-0893395-nnovufno
authors: Bacharaki, Dimitra; Chrysanthopoulou, Evangelia; Grigoropoulou, Sotiria; Giannakopoulos, Panagiotis; Simitsis, Panagiotis; Frantzeskaki, Frantzeska; Flevari, Aikaterini; Karagiannis, Minas; Sardeli, Aggeliki; Kavatha, Dimitra; Antoniadou, Anastasia; Vlahakos, Demetrios
title: Siblings with coronavirus disease 2019 infection and opposite outcome—the hemodialysis’s better outcome paradox: Two case reports
date: 2021-03-25
journal: World J Nephrol
DOI: 10.5527/wjn.v10.i2.21
sha: 7a18c3626c1278e472e7a11cf933731e376d870d
doc_id: 893395
cord_uid: nnovufno

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a highly contagious infection caused by the severe acute respiratory syndrome coronavirus 2 virus and has a unique underlying pathogenesis. Hemodialysis (HD) patients experience high risk of contamination with COVID-19 and are considered to have higher mortality rates than the general population by most but not all clinical series. We aim to highlight the peculiarities in the immune state of HD patients, who seem to have both immune-activation and immune-depression affecting their outcome in COVID-19 infection. CASE SUMMARY: We report the opposite clinical outcomes (nearly asymptomatic course vs death) of two diabetic elderly patients infected simultaneously by COVID-19, one being on chronic HD and the other with normal renal function. They were both admitted in our hospital with COVID-19 symptoms and received the same treatment by protocol. The non-HD sibling deteriorated rapidly and was intubated and transferred to the Intensive Care Unit, where he died despite all supportive care. The HD sibling, although considered more “high-risk” for adverse outcome, followed a benign course and left the hospital alive and well. CONCLUSION: These cases may shed light on aspects of the immune responses to COVID-19 between HD and non-HD patients and stimulate further research in pathophysiology and treatment of this dreadful disease.

The pandemic of coronavirus disease 2019 (COVID-19) by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originating from China on December 2019 poses still a major health and financial problem worldwide [1] . It is a respiratory virus, highly contagious mostly by large droplet transmission, and causes common cold or no symptoms in nearly 80%. However, in a subset of 20%, the infection causes sudden deterioration with severe pneumonia and respiratory failure necessitating intubation, a condition with high mortality rates [2] .

Stable hemodialysis (HD) patients present with the paradox of immune-activation and immune-depression [3] . We report the case of two siblings infected at the same time, one of them on maintenance HD due to end stage renal disease (ESRD) (patient 1, HD) and the other with normal renal function (patient 2, non HD). Although ESRD is associated with increased overall mortality compared to age-matched controls [4] and in particular with COVID-19 [5, 6] , the sibling on HD survived and the other died from multiorgan failure attributed to COVID-19 infection. This case report emphasizes the need for further studies to discover prognostic markers, which will allow us to plan more effective treatment algorithms.

We report the contrasting outcome of two Caucasian diabetic, elderly brothers simultaneously infected by COVID-19 and referred to our hospital early in the course of disease. The laboratory timeline from admission to outcome is shown in Figure 1 . 

Patient 1: He had been hospitalized and treated in a private clinic with HD facilities for diabetic foot and had completed a 10-d course with antibiotics (ticarcillin/ clavulanic acid) when he developed fever. Patient 2: He had been visiting his brother regularly during his hospitalization for his leg infection.

Patients 1 and 2: SARS-CoV-2 was detected in a nasopharyngeal swab specimen by real-time reverse-transcriptase polymerase chain reaction on April 23, and the next day both siblings were admitted to our hospital.

Patient 1: ESRD due to diabetic nephropathy, maintained on regular HD for 6 years.

Patient 2: Obese patient with type 2 diabetes mellitus and normal kidney function.

Patients 1 and 2 have no special personal and family history. 

Laboratory assessment shown in Table 1 and Figure 1 . 

Chest computed tomography (CT) revealed bilateral pleural effusions and ground glass infiltration with central distribution, characteristic of COVID-19 pneumonia [7] .

For patient 1, pulmonary infiltration was < 10%, corresponding to a CT severity score of 10 [7] ; while for patient 2, pulmonary infiltration was > 25%-49%, corresponding to a CT severity score of 19.

COVID-19 disease with respiratory involvement. Patient 1 was considered also hypervolemic on admission.

They were both treated for COVID-19, according to the current protocol of the Infectious Disease department, with a loading dose of 200 mg of hydroxychloroquine at day 1, followed by 100 mg b.i.d. for 5 d, along with azithromycin 500 mg daily during the same period time. They both received prophylactic anticoagulation with tinzaparin 3500 IU subcutaneously once daily. March 25, 2021

Volume 10 Issue 2 Patient 1 continued his thrice weekly HD schedule and reached euvolemia within the next week by increasing dialysis ultrafiltration gradually. On HD day, tinzaparin was given only during HD session, at the dialysis circuit.

Patient 1 had a mild COVID-19 disease, while patient 2 deteriorated rapidly into the critical form with severe respiratory failure and eventually died. syndrome requiring intubation and admission to the intensive care unit (ICU). He was placed on intermittent prone position for the first 3 d in ICU with satisfactory response. On day 2 in ICU, his condition was complicated by fast atrial fibrillation, circulatory collapse and acute kidney injury (AKI). Tocilizumab, an interleukin-6 inhibitor, was given intravenously at 8 mg/kg (750 mg) in two infusions, 12 h apart, as per ICU protocol for severe COVID-19. After 2 d, treatment with continuous renal replacement treatment (hemodiafiltration) for AKI was initiated. On day 8 in ICU, he suffered from gastrointestinal bleeding requiring red blood cell transfusions. On May 12, 2020, he developed a gram-negative bacteremia with Pseudomonas aeruginosa and a pneumonia due to Acinetobacter baumanni. On May 15, he was also offered a 2 h duration hemoadsorption-session with hemoadsorber HA-330 (Jafron, adsorbent material styrene divinylbenzene copolymers, Jafron, Zhuhai, China) as per ICU protocol. HA-330 filters are used as "salvage therapy" in critically ill septic patients with multiorgan failure (renal failure included). Hemoadsorption was not continued because of lack of improvement and on May 21, 2020 he died because of septic shock and multiorgan failure. SARS-CoV-2 was detected in repeated nasopharyngeal swab specimens throughout the ICU stay.

We present the case of two elderly diabetic brothers infected with COVID-19. The younger brother on HD for 6 years, complicated with peripheral artery disease, diabetic foot with gangrene and malnutrition survived and left the hospital alive and well. The older brother with arterial hypertension and normal renal function had a turbulent course, was intubated and eventually died in ICU from sepsis.

The clinical question on outcome of COVID-19 infection in patients on HD remains controversial. The European Renal Association COVID-19 Database collaboration, including 768 dialysis patients, concluded that the 28-d probability of death with COVID-19 in patients on dialysis is high (25% for all patients and 33.5% among those admitted in the hospital) and is associated predominantly with frailty and also with age. Surprisingly none of the known co-morbidities showed statistical significance by multivariate analysis, apart from obesity > 35 kg/m 2 BMI and heart failure [5] . The much larger OpenSafely platform concluded that dialysis or ESRD (kidney dialysis around 24.000 patients) was associated with an almost four-fold increased risk of COVID-19 related deaths. Age above 60 years, diabetes and obesity > 35 kg/m 2 were also independent risk factors for mortality [6] . Other studies from Spain [8] and United States [9] reported a high COVID-19 related mortality among dialysis patients. In contrast, Naaraayan et al [10] found that patients with ESRD-HD have a milder course of COVID-19 illness. These discrepancies may be in part due to the unique pathogenesis of COVID-19 with two distinct immune responses from the host, as recently described [11] , or to differences in the genetic background.

To evaluate the severity of the clinical condition of the siblings at baseline, we measured the total comorbidity burden by the use of Charlson comorbidity index [12] . The index score was 7 for patient 1 and 4 for patient 2, corresponding to an estimated 10-year survival rate of 0% and 53%, respectively. Of note, according to the Clinical Frailty Scale, both brothers had the same high frailty score of 7 on admission [13] .

From a laboratory point of view (radiology and blood panel), the HD patient had a better profile from the start, according the data emerged from the general population [14] . He appeared "less inflamed" on admission (Table 1 and Figure 1 ) with lower WBC, no lymphopenia, lower neutrophil to lymphocyte ratio [15] , less CRP and ferritin [16] levels and lower pulmonary CT imaging score. Other positive prognostic markers for the HD patient in the first 5 d of admission were lower lactate dehydrogenase [17] and d-dimers [18] (Figure 1 ). Of note, both siblings had gastrointestinal bleeding, which has been reported as one of the manifestations of COVID-19 infection [19] .

Cardiac troponin was not predictive of outcome, although it has been described as predictive in a study [14] , notably with no dialysis patients included. Increased troponin levels in patients with kidney disease may be due to cardiac injury associated with chronic structural heart disease rather than acute ischemia, especially when the levels do not change rapidly over time [20] . Interestingly troponin levels were high from the admission in the HD patient and decreased afterwards. On the contrary, they were low in the non-survivor and started to rise only after intubation and AKI.

The strength of this report is that it involves two brothers with presumably similar genetic background and similar co-morbidities, except for the renal function. To the best of our knowledge, this is the first report of COVID-19 disease in a family with member(s) maintained on chronic HD.

We report the opposite outcome of two diabetic elderly brothers infected simultaneously by COVID-19, in which, despite the odds, the one on HD survived and the other with normal renal function followed the typical severe form and died. The surprising different outcome of these two brothers questions the relevance of HD as an independent risk factor of COVID-19-related death and emphasizes the need for further research.

Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Aspects of immune dysfunction in end-stage renal disease

Comorbidities and their impact on outcome in patients with end-stage renal disease

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Factors associated with COVID-19-related death using OpenSAFELY

Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19

COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States

End-Stage Renal Disease Patients on Chronic Hemodialysis Fare Better With COVID-19: A Retrospective Cohort Study From the New York Metropolitan Region

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

A global clinical measure of fitness and frailty in elderly people

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis

D-dimer levels on admission to predict inhospital mortality in patients with Covid-19

Uncommon presentation of COVID-19: Gastrointestinal bleeding

Plasma elimination of cardiac troponin I in end-stage renal disease

We acknowledge the support and contribution in the management of the COVID-19 infected patients of doctors Kalogeropoulou S, Katsoudas S, Gounari P, Nikolopoulos P and Tsotsorou O in the Nephrology Department and doctors Skyllas G, Paramythiotou E and Rizos M in the ICU Department. We would also like to thank Professors Armaganidis A and Dimopoulos G for their support and guidance in the management of the severely infected COVID-19 patients in the ICU.

 Volume 10  Issue 2